200 related articles for article (PubMed ID: 28403211)
1. The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya.
Alsallaq RA; Buttolph J; Cleland CM; Hallett T; Inwani I; Agot K; Kurth AE
PLoS One; 2017; 12(4):e0175447. PubMed ID: 28403211
[TBL] [Abstract][Full Text] [Related]
2. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
[TBL] [Abstract][Full Text] [Related]
3. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community.
Alsallaq RA; Baeten JM; Celum CL; Hughes JP; Abu-Raddad LJ; Barnabas RV; Hallett TB
PLoS One; 2013; 8(1):e54575. PubMed ID: 23372738
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.
Pretorius C; Stover J; Bollinger L; Bacaër N; Williams B
PLoS One; 2010 Nov; 5(11):e13646. PubMed ID: 21079767
[TBL] [Abstract][Full Text] [Related]
5. Modeling the impact on HIV incidence of combination prevention strategies among men who have sex with men in Beijing, China.
Lou J; Blevins M; Ruan Y; Vermund SH; Tang S; Webb GF; Shepherd BE; He X; Lu H; Shao Y; Qian HZ
PLoS One; 2014; 9(3):e90985. PubMed ID: 24626165
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
7. Economics of antiretroviral treatment vs. circumcision for HIV prevention.
Bärnighausen T; Bloom DE; Humair S
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21271-6. PubMed ID: 23223563
[TBL] [Abstract][Full Text] [Related]
8. Gender-Specific Combination HIV Prevention for Youth in High-Burden Settings: The MP3 Youth Observational Pilot Study Protocol.
Buttolph J; Inwani I; Agot K; Cleland CM; Cherutich P; Kiarie JN; Osoti A; Celum CL; Baeten JM; Nduati R; Kinuthia J; Hallett TB; Alsallaq R; Kurth AE
JMIR Res Protoc; 2017 Mar; 6(3):e22. PubMed ID: 28274904
[TBL] [Abstract][Full Text] [Related]
9. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
[TBL] [Abstract][Full Text] [Related]
10. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
11. Large benefits to youth-focused HIV treatment-as-prevention efforts in generalized heterosexual populations: An agent-based simulation model.
Mittler JE; Murphy JT; Stansfield SE; Peebles K; Gottlieb GS; Abernethy NF; Reid MC; Goodreau SM; Herbeck JT
PLoS Comput Biol; 2019 Dec; 15(12):e1007561. PubMed ID: 31846456
[TBL] [Abstract][Full Text] [Related]
12. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
Binagwaho A; Pegurri E; Muita J; Bertozzi S
PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
[TBL] [Abstract][Full Text] [Related]
13. Assessing Progress, Impact, and Next Steps in Rolling Out Voluntary Medical Male Circumcision for HIV Prevention in 14 Priority Countries in Eastern and Southern Africa through 2014.
Kripke K; Njeuhmeli E; Samuelson J; Schnure M; Dalal S; Farley T; Hankins C; Thomas AG; Reed J; Stegman P; Bock N
PLoS One; 2016; 11(7):e0158767. PubMed ID: 27441648
[TBL] [Abstract][Full Text] [Related]
14. Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response.
Baggaley R; Dalal S; Johnson C; Macdonald V; Mameletzis I; Rodolph M; Figueroa C; Samuelson J; Verster A; Doherty M; Hirnschall G
J Int AIDS Soc; 2016; 19(1):21348. PubMed ID: 27989271
[TBL] [Abstract][Full Text] [Related]
15. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
[TBL] [Abstract][Full Text] [Related]
16. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
Alistar SS; Owens DK; Brandeau ML
PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
[TBL] [Abstract][Full Text] [Related]
18. Impact and Cost of the HIV/AIDS National Strategic Plan for Mozambique, 2015-2019--Projections with the Spectrum/Goals Model.
Korenromp EL; Gobet B; Fazito E; Lara J; Bollinger L; Stover J
PLoS One; 2015; 10(11):e0142908. PubMed ID: 26565696
[TBL] [Abstract][Full Text] [Related]
19. Mathematical Model Impact Analysis of a Real-Life Pre-exposure Prophylaxis and Treatment-As-Prevention Study Among Female Sex Workers in Cotonou, Benin.
Geidelberg L; Mitchell KM; Alary M; Mboup A; Béhanzin L; Guédou F; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Silhol R; Cianci F; Vickerman P; Boily MC
J Acquir Immune Defic Syndr; 2021 Feb; 86(2):e28-e42. PubMed ID: 33105397
[TBL] [Abstract][Full Text] [Related]
20. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel.
Ginsberg GM; Chemtob D
BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
